Response to chemotherapy according to genetic polymorphism.
| Genotype | n (%) | Chi-Square Test | Logistic regression analysis | ||||
|---|---|---|---|---|---|---|---|
| Responder | Nonresponder | χ2 | P | OR | 95%CI | P | |
| ERCC1 118 (C/C) | 21 (67.74) | 10 (32.26) | |||||
| C/T + T/T | 21 (72.41) | 8 (27.59) | 0.156 | 0.782 | 0.792 | 0.253-2.486 | 0.690 |
| XPD 751 (A/A) | 34 (58.62) | 14 (41.38) | |||||
| A/C + C/C | 8 (66.67) | 4 (33.33) | 0.079 | 0.740 | 1.058 | 0.224-4.991 | 0.943 |
| XPG 46 (C/C) | 28 (87.50) | 4 (12.50) | |||||
| C/T + T/T | 14 (50.00) | 14 (50.00) | 10 | 0.002 | 7.000 | 1.940-25.255 | 0.003 |
| XRCC1 399 (G/G) | 27 (84.38) | 5 (15.62) | |||||
| G/A + A/A | 15 (53.57) | 13 (46.43) | 6.747 | 0.012 | 4.680 | 1.397-15.682 | 0.009 |
Frequency of the genotypes and their distribution in 42 patients with complete, partial response or stable disease (responders) and 18 with disease progression (nonresponders).